Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Afatinib

Afatinib: Targeted Therapy for Lung Cancer Revolutionized

Introduction

In the rapidly evolving world of oncology, targeted therapies have transformed the landscape of cancer treatment. One such powerful weapon is Afatinib, a second-generation, irreversible tyrosine kinase inhibitor (TKI) that has significantly improved the treatment outcomes in non-small cell lung cancer (NSCLC) patients with specific genetic mutations. Approved for clinical use by the FDA in 2013, Afatinib has since become a standard-of-care agent for EGFR mutation-positive NSCLC.

Afatinib:

  • Generic Name: Afatinib

  • Brand Name: Gilotrif (by Boehringer Ingelheim)

  • Drug Class: Tyrosine kinase inhibitor (TKI)

  • Target: Epidermal Growth Factor Receptor (EGFR) family

  • Route of Administration: Oral tablets

Afatinib is an oral, irreversible inhibitor of the ErbB family of tyrosine kinases, which includes EGFR (ErbB1), HER2 (ErbB2), HER3, and HER4. Unlike earlier TKIs that reversibly bind to EGFR, Afatinib permanently disables these receptors, leading to longer-lasting suppression of downstream signaling pathways.

Mechanism of Action:

Afatinib covalently binds to cysteine residues in the kinase domain of EGFR and HER2, irreversibly inhibiting their activity. This prevents the autophosphorylation of receptors and subsequent activation of signaling pathways responsible for:

  • Cell proliferation

  • Survival

  • Angiogenesis

  • Metastasis

By blocking these pathways, Afatinib induces cell cycle arrest and apoptosis in cancer cells harboring EGFR mutations.

Indications and Uses:

Afatinib is primarily indicated for:

1. Metastatic Non-Small Cell Lung Cancer (NSCLC)

Approved for first-line treatment in patients with:

  • EGFR exon 19 deletions

  • EGFR exon 21 (L858R) substitution mutations

These mutations are most prevalent in:

  • Non-smokers

  • Females

  • Patients of East Asian descent

2. Squamous Cell Carcinoma of the Lung (Second-line)

Afatinib is also indicated as a second-line treatment in advanced squamous NSCLC, following progression after platinum-based chemotherapy.

Pharmacokinetics and Dosage:

Parameter Value
Bioavailability ~92%
Time to Peak (Tmax) 2–5 hours
Half-life ~37 hours
Metabolism Minimal hepatic metabolism (mainly via covalent protein binding)
Elimination Primarily fecal (85%), renal (~5%)
Usual Adult Dose 40 mg orally once daily (can be adjusted based on tolerance)

Afatinib should be taken at least 1 hour before or 2 hours after a meal to enhance absorption.

Clinical Trials and Efficacy

LUX-Lung 3 Trial

  • Compared Afatinib to cisplatin-pemetrexed in EGFR-mutant NSCLC.

  • Results: Afatinib significantly improved progression-free survival (PFS) — 11.1 vs. 6.9 months.

LUX-Lung 6 Trial

  • Similar study in Asian population.

  • Afatinib improved PFS (11.0 vs. 5.6 months) and quality of life.

LUX-Lung 8 Trial

  • Compared Afatinib to erlotinib in squamous NSCLC (post-chemotherapy).

  • Afatinib improved overall survival (OS) and disease control rate.

These trials cemented Afatinib's role as a first-line therapy in EGFR-mutated NSCLC and an option for chemotherapy-refractory squamous NSCLC.

Adverse Effects:

Afatinib is associated with a predictable set of side effects due to its mechanism of action on normal epithelial tissues.

Common Side Effects:

Symptom Incidence
Diarrhea >90%
Rash/acneiform eruptions ~80%
Stomatitis ~70%
Paronychia ~55%
Dry skin Common
Decreased appetite Common

Serious Adverse Events:

  • Interstitial Lung Disease (ILD)

  • Severe hepatotoxicity

  • Keratitis

  • Cardiac dysfunction (rare)

Dose adjustments or interruptions are common in clinical practice to manage side effects.

Dosing Modifications:

Toxicity Recommendation
Grade 1-2 Continue with monitoring
Grade 3 or persistent Grade 2 Interrupt and reduce dose (e.g., from 40 mg → 30 mg)
Severe or intolerable toxicity Discontinue permanently

Typical dose steps: 40 mg → 30 mg → 20 mg

Resistance to Afatinib:

Like other TKIs, resistance to Afatinib typically develops within 1–2 years due to:

  • Secondary EGFR mutations (e.g., T790M)

  • MET amplification

  • Histologic transformation (e.g., to small cell lung cancer)

  • Activation of bypass signaling pathways

Next Steps After Resistance:

  • Osimertinib (a third-generation TKI) is often used if T790M mutation is detected.

  • Biopsy and liquid biopsy (cfDNA testing) can guide further treatment.

Comparing Afatinib with Other EGFR Inhibitors:

Drug Generation Binding EGFR Mutations T790M Activity Approved For
Gefitinib 1st Reversible Exon 19, 21 ❌ NSCLC
Erlotinib 1st Reversible Exon 19, 21 ❌ NSCLC, Pancreatic
Afatinib 2nd Irreversible Exon 19, 21 ❌ NSCLC, Squamous NSCLC
Osimertinib 3rd Irreversible Exon 19, 21 ✅ NSCLC w/ T790M or frontline use

Afatinib offers a broader spectrum by targeting HER2 and other ErbB receptors, but lacks T790M efficacy.

Role in Personalized Medicine:

Afatinib epitomizes the move toward precision oncology:

  • Therapy guided by molecular profiling

  • Improved survival and quality of life compared to chemotherapy

  • Role in liquid biopsies, mutation panels, and NGS (next-generation sequencing)

Companion diagnostics are essential before initiating Afatinib:

  • PCR-based assays

  • Next-gen sequencing panels

  • EGFR mutation status must be confirmed prior to starting therapy

Emerging Research and Future Directions:

Combinations with Immunotherapy

  • EGFR TKIs + PD-1/PD-L1 inhibitors are under investigation, though concerns remain due to increased toxicity (e.g., pneumonitis).

Resistance Mutation Overlap

  • Research into bispecific antibodies and dual inhibitors targeting EGFR and MET.

Global Access

  • WHO is assessing Afatinib for essential medicines lists, particularly in regions with high EGFR-mutant NSCLC rates.

Patient Counseling Tips:

  • Adherence is critical. Take at the same time daily.

  • Avoid food around dosing for best absorption.

  • Hydration and anti-diarrheal medication may be needed.

  • Report new breathing problems or vision changes immediately.

  • Routine liver and kidney monitoring is advised.

Conclusion:

Afatinib represents a milestone in the treatment of EGFR-mutated non-small cell lung cancer. By irreversibly blocking multiple ErbB receptors, it achieves deeper and more sustained responses than earlier TKIs. Though resistance eventually develops, Afatinib provides patients with valuable progression-free time and better quality of life. As oncology moves deeper into the era of precision medicine, drugs like Afatinib will continue to shape the future of cancer care—offering personalized, mutation-specific options for those who need them most.

References:

  1. Sequist LV, et al. LUX-Lung 3 Study. J Clin Oncol.

  2. Yang JC, et al. LUX-Lung 6 Study. Lancet Oncol.

  3. Soria J-C, et al. LUX-Lung 8 Trial. Lancet Oncol.

  4. Boehringer Ingelheim. Gilotrif® Prescribing Information.

  5. FDA Label for Afatinib

  6. NCCN Guidelines for NSCLC

  7. Mok TS, et al. Osimertinib in T790M Resistance. N Engl J Med.